- Home
- FLC vs CRVS Comparison
FLC vs CRVS Comparison
Compare FLC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- CRVS
- Stock Information
- Founded
- FLC 2003
- CRVS 2014
- Country
- FLC United States
- CRVS United States
- Employees
- FLC N/A
- CRVS N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- CRVS Health Care
- Exchange
- FLC Nasdaq
- CRVS Nasdaq
- Market Cap
- FLC 180.6M
- CRVS 516.0M
- IPO Year
- FLC N/A
- CRVS 2016
- Fundamental
- Price
- FLC $16.59
- CRVS $5.10
- Analyst Decision
- FLC
- CRVS Strong Buy
- Analyst Count
- FLC 0
- CRVS 5
- Target Price
- FLC N/A
- CRVS $12.38
- AVG Volume (30 Days)
- FLC 37.8K
- CRVS 1.7M
- Earning Date
- FLC 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- FLC 6.64%
- CRVS N/A
- EPS Growth
- FLC N/A
- CRVS N/A
- EPS
- FLC N/A
- CRVS N/A
- Revenue
- FLC N/A
- CRVS N/A
- Revenue This Year
- FLC N/A
- CRVS N/A
- Revenue Next Year
- FLC N/A
- CRVS N/A
- P/E Ratio
- FLC N/A
- CRVS N/A
- Revenue Growth
- FLC N/A
- CRVS N/A
- 52 Week Low
- FLC $12.62
- CRVS $1.30
- 52 Week High
- FLC $15.45
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FLC 44.20
- CRVS 36.16
- Support Level
- FLC $16.46
- CRVS $4.93
- Resistance Level
- FLC $16.89
- CRVS $6.47
- Average True Range (ATR)
- FLC 0.22
- CRVS 0.40
- MACD
- FLC -0.01
- CRVS 0.06
- Stochastic Oscillator
- FLC 36.00
- CRVS 29.74
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).